share_log

Concerns Surrounding Shenzhen Weiguang Biological Products' (SZSE:002880) Performance

Concerns Surrounding Shenzhen Weiguang Biological Products' (SZSE:002880) Performance

围绕深圳微光生物制品 (SZSE: 002880) 业绩的担忧
Simply Wall St ·  2023/11/02 18:08

Following the solid earnings report from Shenzhen Weiguang Biological Products Co., Ltd. (SZSE:002880), the market responded by bidding up the stock price. However, we think that shareholders should be cautious as we found some worrying factors underlying the profit.

继深圳维光生物制品有限公司(SZSE:002880)发布稳健的财报之后,市场的回应是提高了股价。但是,我们认为股东应该谨慎行事,因为我们发现了利润背后的一些令人担忧的因素。

View our latest analysis for Shenzhen Weiguang Biological Products

查看我们对深圳微光生物制品的最新分析

earnings-and-revenue-history
SZSE:002880 Earnings and Revenue History November 2nd 2023
深圳证券交易所:002880 收益和收入记录 2023 年 11 月 2 日

The Impact Of Unusual Items On Profit

不寻常物品对利润的影响

To properly understand Shenzhen Weiguang Biological Products' profit results, we need to consider the CN¥21m gain attributed to unusual items. We can't deny that higher profits generally leave us optimistic, but we'd prefer it if the profit were to be sustainable. When we crunched the numbers on thousands of publicly listed companies, we found that a boost from unusual items in a given year is often not repeated the next year. And, after all, that's exactly what the accounting terminology implies. If Shenzhen Weiguang Biological Products doesn't see that contribution repeat, then all else being equal we'd expect its profit to drop over the current year.

为了正确理解深圳维光生物制品的利润业绩,我们需要考虑归因于不寻常物品的2100万元人民币的收益。我们不能否认,更高的利润通常使我们感到乐观,但如果利润是可持续的,我们更愿意这样做。当我们计算数千家上市公司的数字时,我们发现,特定年份中不寻常的项目所带来的提振通常不会在第二年重演。而且,毕竟,这正是会计术语的含义。如果深圳维光生物制品没有看到这种贡献重演,那么在其他条件相同的情况下,我们预计其利润将在本年度下降。

That might leave you wondering what analysts are forecasting in terms of future profitability. Luckily, you can click here to see an interactive graph depicting future profitability, based on their estimates.

这可能会让你想知道分析师对未来盈利能力的预测。幸运的是,您可以单击此处查看根据他们的估计描绘未来盈利能力的交互式图表。

Our Take On Shenzhen Weiguang Biological Products' Profit Performance

我们对深圳维光生物制品盈利表现的看法

Arguably, Shenzhen Weiguang Biological Products' statutory earnings have been distorted by unusual items boosting profit. Because of this, we think that it may be that Shenzhen Weiguang Biological Products' statutory profits are better than its underlying earnings power. Nonetheless, it's still worth noting that its earnings per share have grown at 7.3% over the last three years. The goal of this article has been to assess how well we can rely on the statutory earnings to reflect the company's potential, but there is plenty more to consider. With this in mind, we wouldn't consider investing in a stock unless we had a thorough understanding of the risks. For example - Shenzhen Weiguang Biological Products has 1 warning sign we think you should be aware of.

可以说,深圳维光生物制品的法定收益因不寻常的项目而被扭曲了,从而提高了利润。正因为如此,我们认为深圳维光生物制品的法定利润可能优于其潜在的盈利能力。尽管如此,仍然值得注意的是,其每股收益在过去三年中增长了7.3%。本文的目的是评估我们可以多大程度地依靠法定收益来反映公司的潜力,但还有很多需要考虑的地方。考虑到这一点,除非我们对风险有透彻的了解,否则我们不会考虑投资股票。例如,深圳微光生物制品有 1 个警告标志,我们认为你应该注意。

This note has only looked at a single factor that sheds light on the nature of Shenzhen Weiguang Biological Products' profit. But there is always more to discover if you are capable of focussing your mind on minutiae. Some people consider a high return on equity to be a good sign of a quality business. While it might take a little research on your behalf, you may find this free collection of companies boasting high return on equity, or this list of stocks that insiders are buying to be useful.

这份报告仅研究了揭示深圳维光生物制品利润性质的单一因素。但是,如果你能够将注意力集中在细节上,总会有更多值得发现的地方。有些人认为高股本回报率是高质量业务的好兆头。尽管可能需要代表你进行一些研究,但你可能会发现这份免费收集的拥有高股本回报率的公司,或者这份内部人士正在购买的股票清单很有用。

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

对这篇文章有反馈吗?对内容感到担忧?直接联系我们。 或者,给编辑团队 (at) simplywallst.com 发送电子邮件。
Simply Wall St的这篇文章本质上是笼统的。我们仅使用公正的方法根据历史数据和分析师的预测提供评论,我们的文章无意作为财务建议。它不构成买入或卖出任何股票的建议,也没有考虑到您的目标或财务状况。我们的目标是为您提供由基本数据驱动的长期重点分析。请注意,我们的分析可能不考虑最新的价格敏感型公司公告或定性材料。简而言之,华尔街没有持有任何上述股票的头寸。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发